Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease

被引:29
作者
He, Li-Hong [1 ,2 ]
Yao, Dun-Han [2 ]
Wang, Ling-Yun [2 ]
Zhang, Lei [2 ]
Bai, Xue-Li [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
[2] Lanzhou Univ, Hosp Lanzhou Univ 1, Clin Med Coll 1, Dept Gen Surg, Lanzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
gut microbiota; non-alcoholic fatty liver disease; immune; metabolism; gut-liver axis; RANDOMIZED CLINICAL-TRIAL; INTESTINAL MICROBIOTA; OBESE CHILDREN; STEATOHEPATITIS; DIET; MICE; FIBROSIS; ALCOHOL; CELLS; NAFLD;
D O I
10.3389/fmicb.2021.761836
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of end-stage liver disease, leading to a rapidly growing global public health burden. The term "gut microbiome (GM)" refers to the approximately 100 trillion microbial cells that inhabit the host's gastrointestinal tract. There is increasing evidence that GM is involved in the pathogenesis of NAFLD and may be a potential target for intervention. To explore GM-based strategies for precise diagnosis and treatment of NAFLD, great efforts have been made to develop a comprehensive and in-depth understanding of the host-microbe interaction. This review evaluates this interaction critically, mainly considering the intricate regulation of the metabolism, immunity, and inflammatory status during the evolution of the disease pathogenesis, revealing roles for the GM in NAFLD by examining advances in potential mechanisms, diagnostics, and modulation strategies.Synopsis: Considering the intricate metabolic and immune/inflammatory homeostasis regulation, we evaluate the latest understanding of the host-microbe interaction and reveal roles for the gastrointestinal microbiome in NAFLD. Strategies targeting the gastrointestinal microbiome for the diagnosis and treatment of NAFLD are proposed.
引用
收藏
页数:13
相关论文
共 144 条
  • [1] Abdel Monem Sameh M, 2017, Euroasian J Hepatogastroenterol, V7, P101, DOI 10.5005/jp-journals-10018-1226
  • [2] Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells
    Adar, T.
    Ben Ya'acov, A.
    Lalazar, G.
    Lichtenstein, Y.
    Nahman, D.
    Mizrahi, M.
    Wong, V.
    Muller, B.
    Rawlin, G.
    Ilan, Y.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 167 (02) : 252 - 260
  • [3] The gut-liver axis in liver disease: Pathophysiological basis for therapy
    Albillos, Agustin
    de Gottardi, Andrea
    Rescigno, Maria
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 558 - 577
  • [4] Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis
    Alisi, A.
    Bedogni, G.
    Baviera, G.
    Giorgio, V.
    Porro, E.
    Paris, C.
    Giammaria, P.
    Reali, L.
    Anania, F.
    Nobili, V.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (11) : 1276 - 1285
  • [5] Aller R, 2011, EUR REV MED PHARMACO, V15, P1090
  • [6] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [7] Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
    Anh, Sang Bong
    Jun, Dae Won
    Kang, Bo-Kyeong
    Lim, Jong Hyun
    Lim, Sanghyun
    Chung, Myung-Jun
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
    Arab, Juan P.
    Karpen, Saul J.
    Dawson, Paul A.
    Arrese, Marco
    Trauner, Michael
    [J]. HEPATOLOGY, 2017, 65 (01) : 350 - 362
  • [9] Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
    Aron-Wisnewsky, Judith
    Vigliotti, Chloe
    Witjes, Julia
    Le, Phuong
    Holleboom, Adriaan G.
    Verheij, Joanne
    Nieuwdorp, Max
    Clement, Karine
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (05) : 279 - 297
  • [10] Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis
    Bajaj, J. S.
    Heuman, D. M.
    Hylemon, P. B.
    Sanyal, A. J.
    Puri, P.
    Sterling, R. K.
    Luketic, V.
    Stravitz, R. T.
    Siddiqui, M. S.
    Fuchs, M.
    Thacker, L. R.
    Wade, J. B.
    Daita, K.
    Sistrun, S.
    White, M. B.
    Noble, N. A.
    Thorpe, C.
    Kakiyama, G.
    Pandak, W. M.
    Sikaroodi, M.
    Gillevet, P. M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1113 - 1125